CN1666976A - L-chelated zinc arginine - Google Patents
L-chelated zinc arginine Download PDFInfo
- Publication number
- CN1666976A CN1666976A CN 200410016923 CN200410016923A CN1666976A CN 1666976 A CN1666976 A CN 1666976A CN 200410016923 CN200410016923 CN 200410016923 CN 200410016923 A CN200410016923 A CN 200410016923A CN 1666976 A CN1666976 A CN 1666976A
- Authority
- CN
- China
- Prior art keywords
- zinc
- arginine
- people
- protein
- soft
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940038879 chelated zinc Drugs 0.000 title 1
- UJNPHNKJSKIVTE-SCGRZTRASA-L zinc;(2s)-2-amino-5-(diaminomethylideneamino)pentanoate Chemical compound [Zn+2].[O-]C(=O)[C@@H](N)CCCNC(N)=N.[O-]C(=O)[C@@H](N)CCCNC(N)=N UJNPHNKJSKIVTE-SCGRZTRASA-L 0.000 title 1
- 239000011701 zinc Substances 0.000 claims abstract description 66
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 64
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 63
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 14
- 229930064664 L-arginine Natural products 0.000 claims abstract description 14
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 108010016626 Dipeptides Proteins 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 11
- 239000000126 substance Substances 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 230000035790 physiological processes and functions Effects 0.000 abstract description 4
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 239000002574 poison Substances 0.000 abstract description 2
- 231100000614 poison Toxicity 0.000 abstract description 2
- 238000010170 biological method Methods 0.000 abstract 1
- 230000003862 health status Effects 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 description 17
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 17
- 235000009697 arginine Nutrition 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 230000008569 process Effects 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000013522 chelant Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 2
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 235000002949 phytic acid Nutrition 0.000 description 2
- 229940068041 phytic acid Drugs 0.000 description 2
- 239000000467 phytic acid Substances 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 239000011670 zinc gluconate Substances 0.000 description 2
- 229960000306 zinc gluconate Drugs 0.000 description 2
- 235000011478 zinc gluconate Nutrition 0.000 description 2
- 239000011576 zinc lactate Substances 0.000 description 2
- 229940050168 zinc lactate Drugs 0.000 description 2
- 235000000193 zinc lactate Nutrition 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229960001763 zinc sulfate Drugs 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- QAARCAVCHCWRKQ-WCCKRBBISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;zinc Chemical compound [Zn].OC(=O)[C@@H](N)CCCNC(N)=N QAARCAVCHCWRKQ-WCCKRBBISA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 206010019759 Hepatitis chronic persistent Diseases 0.000 description 1
- 206010060766 Heteroplasia Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241001482237 Pica Species 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003883 azoospermia Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- -1 creme Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000018528 secretion by tissue Effects 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
This invention provides a new molecule belongs to soft zinc quality in soft matter. L-arginine chelating zinc made through chemical biological method, it can supply the needed zinc to living body. It can be used to protect several kinds of diseases bring by zinc lack and can make people in inferior-health status to recover to health status. Comparing to the zinc supply product now, it is easy to dissolve and absorb, pure and safety of its quality and no poison effect. It is a new substance that more accord with people's physiological function need and matching with people's bioenergy conversion. The figure is its formula.
Description
Technical field
The invention belongs to recruit's structure of biological medicine field of health care products, be particularly related to a kind of recruit and be L-arginine chelating zinc, this invention comes true the design design that the L-arginine combines with zinc element, and novel substance can change the actual state that metallic element zinc is difficult for being absorbed by the body; The recruit L-arginine chelating zinc that forms can replenish the nutrition of necessary arginine of organism and zinc and treat and prevent various diseases, also can adjust the sub-health state of human body.
Background technology
Zinc be at present known to one of several trace elements of needed by human, its content in vivo is only second to iron and occupies second of trace element.Zinc more and more comes into one's own to people's Physique growth, psychological development and health affected.Zinc and endocrine system, immunologic function, DNA, protein, collagen is synthetic that close ties are arranged, and it can be compared without any a kind of other trace elements the contribution of human body physiological function.Zinc participates in the synthetic and cellular metabolism of human body 200 plurality of enzymes, regulates glycogen heteroplasia and protein synthesis, and accelerating growth is grown, keep the normal appetite and the sense of taste, raise immunity promotes wound healing, guarantee the normal growth and the function of brain, SOD activity improving, stabilizing cell membrane delays senility, simultaneously, for metabolism, tissue respiration, internal secretions etc. have vital role.The feed rate of infant's zinc is 3-5mg every day; Children and teenager are 10-15mg every day, grownup 15mg every day; Pregnant being pregnent and nursing women 20mg every day; Old people is 15mg every day.
Zinc in the food has the part of different relative molecular masses to link with it in cell by the picked-up of small intestinal cell microvillus.The zinc of 30%-51% during common people only assimilate food, degree of absorption is subjected to influence of various factors.Phytic acid (forming the insolubility mixture with zinc) all hinders its absorption with fiber.When iron and zinc are taken in simultaneously, can interfere with each other absorption.Ethanol injects stomach, finds that ethanol makes zinc combine minimizing with macromolecule protein, and combines increase with low molecular weight protein, thinks that ethanol has the effect that suppresses or delay the zinc absorption.Therefore zinc content is very low in the alcoholic cirrhosis patient body.Zinc is animals and plants and human essential element, is the moiety of enzyme in a lot of important metabolic processes.The zinc of quite a few is stored in bone and the muscle.But these storage capacities can not be organized with other and comparatively fast reach balance.Pertinent data shows that China has 60% children to lack zinc approximately, and it is about 30% that pregnant woman and wet nurse lack the zinc incidence.
Three phases has been experienced in zinc supplementation both at home and abroad: the first-generation is by the inorganic zinc of zine ion and mineral acid be combined into, just belongs to this type of as zinc sulfate.The s-generation is the low molecule organic zinc by zine ion and organic acid be combined into.Representative products has Zinc Gluconate, zinc lactate, zinc glycyrrhetate etc.They have too many side effect and make that zinc can not get using widely always in the process of taking, thereby force scientific circles to be devoted to the research and development of third generation bioprotein zinc emphatically.Present zinc product roughly is divided three classes:
(1) inorganic zinc: with zinc sulfate is representative;
(2) organic zinc: Zinc Gluconate is representative, also has zinc lactate, zinc glycyrrhetate, zinc acetate etc.;
(3) bioprotein zinc: the fermented type product that with the yeast is carrier is main.
Bioprotein zinc is to adopt the refining of new generation biological zinc supplementation product that form of modern biotechnology.Its principal feature is: 1, zinc is carrier with the biological activity protein, combines the natural biological goods with polysaccharide; 2, bioavailability 37%, is inorganic zinc and organic zinc 3-6 times; 3, protein content height, side effect is little, takes safety for a long time.Bioprotein zinc is than going a step further before the first kind, second series products, but still existing molecular weight big, bioavailability is not high enough, and or mixture, because these deficiencies, seek better product and meet more that human-body biological can be changed and the product of physiological requirements is necessary.
Summary of the invention
The present invention is the shortcoming that overcomes existing physical product, and a kind of amino-acid zinc that is called soft zinc matter is provided, L-arginine chelating zinc, and its structural formula is:
Molecular formula: C
12H
26N
8ZnO
4
Molecular weight: 411.7686 (according to relative atomic weight meters in 1989)
English name: L-Argininum Zn of Chelate
Biological chemistry specific name: L-Lysine Zn of Chelate, zinc-amino acid chelate, arginine chelating zinc
Arginine is a kind of basic aminoacids, is important condition amino acid.Though concerning the adult, be not must amino acid, in some situation such as body development is immature or under stressed condition, if lack arginine, just body can not be kept positive nitrogen balance and normal physiological function.Arginine is an integral part in the urea cycle, has extremely important physiological function.Eat arginine more, can increase the activity of arginase in the liver, help the ammonia in the blood to be converted into urea and to excrete.Arginic important metabolic function is the healing effect that promotes wound, can promote the synthetic of collagenous tissue.Arginine can prevent the degeneration of thymus gland, and additional arginine can increase the weight of thymus gland, promotes the growth of thymus gland medium size lymphocyte.Arginine can promote the ripe and differentiation of CD cell in bone and the lymphoglandula.In immunity system, except that lymphocyte, cytophagous vigor is also relevant with arginine.After adding arginine, can activate its enzyme system, making it more can the kill tumor cell or target cell such as bacterium.Arginine can stimulate the high glucemia element of Regular Insulin, pancreas in hypophysis secretion tethelin, prolactin and the pancreas, and these hormones have effect to promoting growth, and is relevant with the intravital immunologic function of raising again simultaneously.In addition, the protein synthesis behind these hormones and the body injury and generation of wound collagen etc. are relevant.
Arginine is the prerequisite material of synthetic polyamine, and polyamines is that the lymphocyte breeding is essential with growth.Arginine also is the necessary composition in the enzymes metabolism approach of NO and citrulline reaction.It can stimulate these organs and tissue secretion hormone, plays the effect of immunologic function.
The arginine safety non-toxic can be used the therapeutic dose of 0.5/kg (body weight) clinically.So, use arginine to innovate optimization as the carrier of zinc, be perfect composite design.
The present invention is set in the micromolecular category of little peptide, and promptly Zui Xiao albumen dipeptides claims little peptide again, and molecular weight is 411.7686, and little peptide is to assemble synthetic under the particular environment with amino acid outside organism, and zinc element also assembling simultaneously gets on.According to soft matter theory and Biological Principles, the hard material that will exist in the world originally in organism external application specific method divides the system combination again, be combined into directly adaptable soft material form of life entity, promptly change the not good essence of its original organism assimilation effect, and show the certain effects of design in advance.
The present invention does not relate to the quality of biological gene substantially, gene template is when carrying out the life assemblage of aminoacid sequence, this process also is accompanied by the transmittance process and the switching process of energy simultaneously, little peptide small molecules of the present invention provides and quickens the material (power) of this transmittance process and switching process, its basic theory is to talk acquired disposition on the basis of molecular genetics (gene transmission) and molecular epidemiology (genetic flaw) inborn factor, because the environment of the existence of life and its own existence has very important interaction, be what and the quality of quality that nutrient substance provides energy, equally vital process has been played very important influence, the possibility that transgenation may also be arranged of improvement of genes has promptly been arranged.Disease is the spontaneous phenomenon of vital process with failing naturally, and the present invention not only can treat the process that the disease that has occurred can delay the nature deterioration process again, and the generation of prevention some diseases in this process, really accomplishes good health and a long life.
Product of the present invention should be returned in zinc supplementation product the 4th class: L-arginine chelating zinc, two amino acid of reason form minimum protein and show that it is active essential, so also can be described as little peptide in conjunction with zinc, with the material class discrimination, are called soft zinc matter.
The present invention is a carrier with two L-arginine, and two L-arginine have formed the little peptide that is similar to natural dipeptides protein-zinc with zinc element and combined zinc.The selection reason of carrier is, amino acid is the proteinic minimum unit that forms, and it is the basic substance of life.The gene relevant with heredity in fact also is the amino acid chain of different order.At present, relevant with human body 28 seed amino acids that have.The peptide chain that this 28 seed amino acid is arranged in the different order different lengths is formed the functional protein of body portion.Have 100 multiple proteins according to statistics.Protein in the meals does not directly constitute the protein in the health, but through after digesting and assimilating, mainly is transformed into amino acid in liver, and these amino acid are reassembled into intravital 100 multiple proteins again according to the needs of human body.Therefore, not protein and amino acid is only the nutrient substance that needed by human body is wanted strictly speaking.
Amino acid can also be worked in coordination with the normal function that VITAMIN and mineral substance are kept body except the base substance as synthetic protein.
The present invention has selected the L-arginine for use, and the L-arginine can increase immunity of organisms, quickens microcirculation, promotes metabolism.Lack arginine and can cause poor growth, immunity degradation.
Select this seed amino acid to form new molecule, can satisfy the not demand of preventing and treating of same-action, different ages, various disease substantially with combining of zinc element.The characteristics that the present invention has CL, easily absorbs, more meeting human-body biological can change and physiological requirements.
Embodiment
The present invention adopts preparation method's preparation of autonomous patent of invention technology (patent No. ZL96116524.3).
Structural formula of the present invention is:
Molecular formula: C
12H
26N
8ZnO
4
Molecular weight: 411.7686
Can make tablet, hard capsule, soft capsule, micro-capsule, granule, oral liquid, injection etc. with it during concrete the use; Also can be made into ointment, creme, emulsion, eye drops of external application etc.
Product proterties of the present invention: this product is the finely powdered white particle, and odorless is little puckery, soluble in water, is insoluble to organic solvents such as ethanol, ether substantially, has water absorbability.Products characteristics of the present invention: dissolve, good absorption has good zinc supplementation effect, and improves the organism fatigue state, more meets the bioenergy conversion and the physiological requirements of human body.
Product mechanism of action of the present invention: L-arginine zinc is a kind of stable water-soluble chelate structure, the essence of little peptide binding substances, oral post-absorption is good, can't combine with oxalic acid, the phytic acid in the food and influence absorption, absorpting form with little peptide ammino acid in small intestine is entered in the body by abundant the absorption, do not need to add Vitamin D3 500,000 I.U/GM and promote to absorb, the danger of having avoided D3 to poison.
Indication of the present invention: be used for growth retardation, young men and women's sexual organ dysplasia, infertility, azoospermia, sexual disorder, malnutrition, apocleisis, pica, pregnant woman wet nurse's health care, stomatocace, postoperative wound healing, hair color, osteoporosis; And can be used for the assisting therapy of meningitic sequela, senile dementia etc.; Also be applicable to disease aid nutrition such as chronic persistent hepatitis that immunity degradation causes, chronic nephritis.
Claims (2)
1, a kind of L-arginine chelating zinc, the recruit shows following feature:
(1) structural formula is:
(2) molecular formula: C
12H
26N
8ZnO
4
(3) molecular weight: 411.7686
2, L-arginine chelating zinc according to claim 1; It is characterized in that two L-arginine have formed the little peptide that is similar to natural dipeptides protein-zinc with zinc element and combined zinc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410016923 CN1666976A (en) | 2004-03-12 | 2004-03-12 | L-chelated zinc arginine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410016923 CN1666976A (en) | 2004-03-12 | 2004-03-12 | L-chelated zinc arginine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1666976A true CN1666976A (en) | 2005-09-14 |
Family
ID=35038285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410016923 Pending CN1666976A (en) | 2004-03-12 | 2004-03-12 | L-chelated zinc arginine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1666976A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116655500A (en) * | 2023-05-30 | 2023-08-29 | 长沙兴嘉生物工程股份有限公司 | A kind of arginine zinc chelate and preparation method thereof |
-
2004
- 2004-03-12 CN CN 200410016923 patent/CN1666976A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116655500A (en) * | 2023-05-30 | 2023-08-29 | 长沙兴嘉生物工程股份有限公司 | A kind of arginine zinc chelate and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101228993B1 (en) | Fermentation and culture method, fermented plant extract, fermented plant extract powder and composition containing the fermented plant extract | |
| CN104224823A (en) | Composition for promoting ketone compound formation | |
| CN109757734A (en) | A kind of polypeptide oral liquor and preparation method thereof | |
| CN107164446A (en) | The preparation method and its antifatigue effect of deer hemepeptide | |
| JP4132635B2 (en) | Uninactivated enzyme-enhanced composition | |
| US20190038769A1 (en) | Micro-rna profiling, compositions, and methods of treating diseases | |
| AU742460B2 (en) | Fatty acids as a diet supplement | |
| CA2514687A1 (en) | Advenced vitamin c-based composition with enhanced biotransformation and utilization of protein and l-carnitine for nutritional supplementation or the like | |
| CN105661554A (en) | Silkworm chrysalis small molecule peptide chelate for improving immunity and preparation method thereof | |
| CN1273533A (en) | I (Robinia Pseudoacacia) lectin and its uses | |
| CN1666976A (en) | L-chelated zinc arginine | |
| CN1467198A (en) | Monozinc di-L-Aspartate | |
| CN1895066A (en) | Anti-body leben tablet (powder) | |
| AU2017101419A4 (en) | Compositions for selenium delivery | |
| CN102613653A (en) | Nutrient beverage containing gamma-aminobutyric acid and preparation method of nutrient beverage | |
| CN101851604B (en) | Production method of human serum albumin | |
| CN107712875A (en) | Black quinoa weight losing meal-replacing | |
| CN1467199A (en) | Monozinc di-L-lysine | |
| CN101199492A (en) | Application of oligomerization xylose and xylito in coating slice coating | |
| CN1158892A (en) | Peptide-containing protein wine | |
| CN114514956A (en) | Gel hollow candy for assisting in feeding pet medicaments, and preparation method and application thereof | |
| CN120718990B (en) | Method for preparing compound pentapeptide with lipid-lowering and blood glucose-lowering functions by utilizing enzymolysis-fermentation-enzymolysis technology and application of compound pentapeptide | |
| CN1666980A (en) | L-chelated calcium arginine | |
| CN108991358A (en) | A kind of auxiliary reducing blood lipid, it is hypoglycemic, alleviate gout health care food and production method | |
| CN1944457A (en) | Glutathione calcium chelate and its preparing method, use and composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |